Recursion Pharmaceuticals Stock

Recursion Pharmaceuticals ROE

The Return on Equity (ROE) of Recursion Pharmaceuticals (RXRX) as of Aug 4, 2026 is -57.01 %. In the previous year, Return on Equity (ROE) was -44.81 % — a change of 27.24% (lower).

ROE

-57.01 %

YoY

27.24%

Last updated:

In 2026, Recursion Pharmaceuticals's return on equity (ROE) was -57.01 %, a 27.24% increase from the -44.81 % ROE in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

ROE Details

Decoding Recursion Pharmaceuticals's Return on Equity (ROE)

Recursion Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Recursion Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Recursion Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Recursion Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Recursion Pharmaceuticals stock

Return on Equity (ROE) of Recursion Pharmaceuticals is -57.01 % in 2026.

Return on Equity (ROE) of Recursion Pharmaceuticals changed from -44.81 % to -57.01 %, representing a 27.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Recursion Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Recursion Pharmaceuticals

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Recursion Pharmaceuticals